Back to Tools
Investor Tools

Return on Equity Analyzer

How to use /Start with your property value and mortgage, then add what the property returns in a year, then compare the paths. The read updates as you type. Your numbers stay on your device.

Live model
04 / The Comparison

Current Path vs. Potential Path

Year 20 +$764K

This view compares the current equity path against a potential redeployment path and a private-lending benchmark using the same starting equity.

Current Path
$4.07M

Year 20 at 10.05% current ROE.

Year 20 Gap
+$764K

Same starting equity, compounded annually.

Potential Path
$4.84M

Year 20 at 11.00% redeployed return.

05101520$0$1.50M$3.00M$4.50M$6.00M
Current Path Private Lending Potential Path
Milestones

Start-of-Year Net Worth - 20 Year View

YearCurrent PathPrivate LendingPotential PathDifference
Year 5
Starting equity compounded annually
$968,516$861,378$1,011,035+$42,519
Year 10
Starting equity compounded annually
$1,563,371$1,236,619$1,703,653+$140,282
Year 15
Starting equity compounded annually
$2,523,581$1,775,326$2,870,754+$347,173
Year 20
Starting equity compounded annually
$4,073,546$2,548,711$4,837,387+$763,841
Decision Read

$600,000 is earning 10.05% today.

If the same equity earns 11.00% instead, the modeled 20-year difference is $763,841 before taxes, transaction costs, and new capital contributions. At a 7.5% private-lending benchmark, that same equity would produce $45,000 before tax and borrower/default risk.

Important Assumptions

This analyzer is an educational planning tool for comparing equity productivity. Paydown and cash flow estimates use simplified NOI yield, mortgage rate, and amortization assumptions and should be confirmed with property-level underwriting. The private-lending benchmark is hypothetical and does not include taxes, transaction costs, borrower/default risk, refinancing fees, financing approvals, market risk, or property-specific due diligence. Returns are modeled from the inputs provided and should be reviewed before making investment decisions.